IHC PathPlex™ from Bethyl

news September 30 2019

Believe in What You See. The tumor microenvironment is complex. Your research doesn’t have to be. Introducing Bethyl’s IHC PathPlex™ Multiplex Antibody Panels. Quickly detect multiple antigens in a single tissue section to gain a clear understanding of the microenvironment without compromising samples.

Advantages of Multiplexing

With the advancement of immunotherapeutics, the urge to understand the tumor microenvironment has never been more pressing. Molecular histopathology has recently been shifting from single-marker immunohistochemistry towards multiplexed marker detection. Multiplex immunohistochemistry maximizes the amount of data acquired from an individual sample. Recent advances in multiplex immunohistochemistry and multispectral imaging facilitate accurate simultaneous analysis of multiple tissue markers. Clinically, understanding of the tumor microenvironment, and subsequent selection of appropriately-targeted therapies, can be augmented by profiling and localizing immune checkpoint proteins. The applications of multiplex immunohistochemistry are numerous, and span clinical, translational, and basic research applications.

IHC PathPlex™

To serve your multiplex research needs, Bethyl introduces IHC PathPlex™ panels to profile the complex tumor microenvironment. Each antibody has been validated for IHC and utilized in a multiplex format by our own scientists via proprietary processes to ensure the highest quality. With over 45 years of experience, Bethyl is recognized as a leading antibody manufacturer trusted by researchers around the world.

Pick any of the three core panels and add one or more antibody of your liking from their immuno-oncology inventory.

IHC PathPlex™ Core Panels

T-Cell I/O Panel

CD3

CD8

PD-L1

Lymphocyte Panel

CD3

CD8

CD20

T, B & M Panel

CD3

CD20

CD68